Novartis Acquires Tourmaline Bio From The US

2025-09-09 02:13:40

Alternative Headline:

(MENAFN- Swissinfo) Swiss pharmaceutical company Novartis is buying in the United States. The biopharmaceutical company Tourmaline Bio is to be acquired for around $1.4 billion (CHF1.1 billion). This content was published on September 9, 2025 - 09:13 1 minute Keystone-SDA

Deutsch de Novartis übernimmt Tourmaline Bio aus den USA Original Read more: Novartis übernimmt Tourmaline Bio aus den US

+Get the most important news from Switzerland in your inbox

Novartis is offering $48 per share in cash, it said in a statement on Tuesday. The transaction is expected to close in the fourth quarter of 2025.

Tourmaline Bio has developed Pacibekitug, a promising monoclonal antibody against systemic inflammation, a major risk factor for cardiovascular disease. The drug is already in advanced Phase 2 trials.

+ How Novartis got ahead on 'incredible' cancer breakthrough

According to the press release, Novartis is thus likely to acquire a phase 3-capable product that complements its own portfolio in the field of cardiovascular diseases.

Translated from German by DeepL/ts

MENAFN09092025000210011054ID1110038697

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.